Policy: STUDY DOCUMENTATION STANDARDS AND DATA MANAGEMENT PRACTICES

1. PURPOSE
1.1. To establish human subject research documentation standards to effectively maintain complete, accurate, and current human subject research records by supplementing federal or state regulations with local policy.
1.2. The policy applies to all personnel who are responsible for collection and maintenance of human subject research documents and data (regardless of format).

2. REVISIONS FROM PREVIOUS VERSIONS
Summary of changes this version:
2.1. Divided policy into two sections to distinguish and specify the concepts of Study Documentation Standards and Data Management Practices, organizing the sections under: General Principles, Procedure, and Evaluation.
2.2. Added a Matrix of Research Documentation Standards (RDS) based on four types of studies and whether FDA sponsor documentation is applicable (see Appendix A).
2.3. Clarified that documentation standards are based on the type of research being performed and the level of risk associated with the study. Document types are categorized as: Essential Documents (ED), Source Documents (SD), Data Collection (DC), or Financial (FN). (see Appendix A).

3. STUDY DOCUMENTATION STANDARDS
3.1. General Principles:
3.1.1. Investigators oversee and delegate responsibilities to research team members to ensure records include a reasonable and suitable guarantee of authenticity and reliability.
3.1.2. Investigators ensure documentation practices protect the privacy of the research subject, maintain confidentiality of study documentation (records) and preserve business continuity.
3.1.3. Investigators or designated personnel ensure records are easily accessible for inspection by authorized institutional officials, and as applicable, the Food and Drug Administration (FDA) or other federal agencies, sponsors and sponsor agents, or funding entities.
3.1.4. Manuals, SOPs, and/or Work Instructions (WIs) must be detailed enough for uniform treatment in executing the protocol and administration of the study.
3.1.5. If the research is investigator-initiated, then the Principal Investigator establishes documentation forms and processes, including revision control methods to record the history of changes and to ensure removal of the superseded versions of procedures and data collection tools.
3.1.6. Research teams generate key documents either to guide study activities or as a result of the conduct of the study.

3.2. Procedures:
3.2.1. Determine the method for how study records will be stored and how to organize paper records in binders with indexes or if digital records, on a secure server with clearly designated folders or indexing. If records are filed separately, place a note (or electronic link) in the primary study file to identify where the separated information is stored.
3.2.2. Maintain confidentiality of research data by replacing direct identifiers with codes. Maintain the key to the codes in a secure in locked storage cabinet or on a secure server.
3.2.3. Do not leave private identifiable or proprietary information exposed on a desk or viewable on a computer screen when leaving one’s workspace unattended.

3.2.4. When transporting private identifiable research data, ensure measures are taken to reduce the risk of unintended loss of confidentiality.

3.2.5. Investigators conducting FDA Regulated research and storing documents electronically, refer to Guidance for Industry: Computerized Systems Used in Clinical Investigations

3.2.6. Develop written SOPs for handling documents and train staff on creating, revising, and filing or archiving documents. Document staff training when revisions occur.

3.2.7. Investigators ensure that study documents are not accidentally or prematurely destroyed before the expiration of prescribed retention periods per institution or sponsor, whichever is longer. (HOP 2.2.1; List of Research and Grants Retention Schedule).

3.2.8. Some sponsors may require investigators to maintain documents not specifically referenced in this policy.

3.3. Evaluation:

3.3.1. Create and use a checklist to efficiently review documents at every filing change to maintain current, complete study records.

3.3.2. Analyze documents and filing at sufficient intervals based on the complexity of the study. The larger the volume of documents, the smaller the frequency of review.

3.3.3. Investigators designate specific staff to manage documents clearly defined in the job description and with tasks delineated in SOPs.

3.3.4. Review SOPs regularly and revise as needed.

3.3.5. Investigators read monitoring reports upon receipt and meet with staff to discuss documentation requirements and needed changes.

4. DATA MANAGEMENT PRACTICES

4.1. General Principles:

4.1.1. Sponsors typically require a specified organization for data and often provide procedures, binders, and forms or web-hosted applications to manage data consistently and, if applicable, across multiple sites.

4.1.2. Investigators understand the vital nature of research records, which must stand alone for each study subject and as a whole for the study to illustrate the conduct and progress of a study.

4.1.3. Study-specific procedures define data collection, e.g., who will collect it, how it will be collected, and where it will be recorded.

4.1.4. Study data may be transcribed from source documents.

4.1.5. Investigators authorize who is allowed to make changes to data and who reviews the changes.

4.1.6. Sharing data that have been published is a tenet of the scientific community. Standards of data sharing are published by national scientific organizations and by federal funding agencies. (See Part 5., References)

4.1.7. Consistent with federal policy and prevailing higher education practices, research data are the property of the HSC. Refer to HOP 12.1.1., Intellectual Property Policy and HOP 7.6.1, Policy Statement Relating to Misconduct or Research Misconduct.

4.1.8. The HSC has the right to access research data and records for all research, performed at HSC, supported by HSC-administered funds, or conducted using HSC facilities and equipment, provided that such access shall be for reasonable cause, at reasonable times and after reasonable notice, except in the event of a bona fide emergency. The HSC right of access continues regardless of the location of the Principal Investigator or of the research data. A written agreement on Disposition of Research Data shall be...
negotiated between the PI and the department chair or dean. These agreements serve to ensure fulfillment of HSC obligations to funding agencies and ensure appropriate access for compliance purposes. See also the UTHSCSA Records Retention Schedule at the following link: http://www.library.uthscsa.edu/university/recordsRRS.cfm.

4.2. Electronic data systems housing study data must comply with federal and state regulations.
   4.2.1. If FDA regulated - Guidance on Electronic Source Data in Clinical Investigations and FDA Guidance for Industry – Computerized Systems Used in Clinical Trials.
   4.2.2. If VA research – Refer to VA Information Security Program
   4.2.3. If HSC research – Refer to HOP 5.8 Information Security
   4.2.4. Implement written procedures for maintaining and for using electronic systems, including adequate backup procedures. Train all RT members who are required to use the system.
   4.2.5. Access to electronic records may require transfer to central retention server(s), should the PI or other key team member leave the institution during the execution of or after the close-out of the study.

4.3. Procedures:
   4.3.1. Before initiating a study, sponsors and investigators train research team (RT) members on data filing procedures.
   4.3.2. Investigators provide adequate supplies to ensure filing systems are maintained.
   4.3.3. Coordinators prepare files in advance of monitoring visits.
   4.3.4. RTs record source data at the time of observation or test result, and initial and date all entries by the person recording the entry. (See Table 1.)
      4.3.4.1. Write all handwritten entries in ink only, legibly, and explain all blanks.
      4.3.4.2. Make corrections using a single line strike out with date, time, and initials to maintain auditable changes without obscuring the original entry. Correction tape or liquid is strictly prohibited.

<table>
<thead>
<tr>
<th>Table 1: Example Source Documents (see also Appendix A, Section SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original Study Documents – Completed Informed Consent Forms (ICF) and Case Report Forms (CRF)</td>
</tr>
<tr>
<td>Records from trial execution or supporting documents on medical history including the following:</td>
</tr>
<tr>
<td>• Medical records</td>
</tr>
<tr>
<td>• Hospital, clinic, &amp; office charts</td>
</tr>
<tr>
<td>• Progress notes, patient visit notes, physician’s notes/orders</td>
</tr>
<tr>
<td>• Records: laboratory, radiology, cardiology, medico-technical departments</td>
</tr>
<tr>
<td>• Pharmacy dispensing records</td>
</tr>
<tr>
<td>• X-Rays, Scans (bone, brain, MRI)</td>
</tr>
<tr>
<td>• Video (angiography, endoscopy)</td>
</tr>
<tr>
<td>• Instrumentation printout: EKG, ECG, Spirometry, etc.</td>
</tr>
<tr>
<td>• Memos to record concerning the study</td>
</tr>
<tr>
<td>• Subjects’ diaries, evaluation checklists, or Quality of Life questionnaires</td>
</tr>
<tr>
<td>• Recorded data from automated instruments</td>
</tr>
<tr>
<td>• Certified transcription of recorded results including dictation (i.e., verified as accurate and complete)</td>
</tr>
<tr>
<td>• Photographs, negatives, microfilm or magnetic media</td>
</tr>
</tbody>
</table>
4.3.5. Set up quality control checks of the transcription as routine practice or practice dual data entry for comparison.
   4.3.5.1. Explain any discrepancies between transcribed data and source data.
   4.3.5.2. Review data on a scheduled basis to identify adverse events, protocol deviations, and data recording errors.

4.3.6. Archive study data in a secure manner at the institution or at an off-site storage area with limited access and a sign-in/out log. See HOP 5.8: Information Security.

5. REFERENCES:

5.1.2. National Institutes of Health (NIH) Data Sharing Policy
5.1.3. National Science Foundation (NSF) Dissemination and Sharing of Research Results. See Award & Administration Guide (AAG) Chapter VI.D.4.
5.1.5. UTHSCSA Records Retention Schedule at the following link: http://www.library.uthscsa.edu/university/recordsRRS.cfm and http://libweb.uthscsa.edu/university/rrsResearch.pdf
### Office of Clinical Research

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Clinical Trial Management</th>
<th>Issued:</th>
<th>May 25, 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section</td>
<td>Resource Management</td>
<td>Effective:</td>
<td>May 12, 2014</td>
</tr>
<tr>
<td>Policy</td>
<td>Study Documentation Standards and Data Management Practices</td>
<td>Version:</td>
<td>2.0</td>
</tr>
</tbody>
</table>

**Appendix A:** Research Documentation Standards Matrix

---

SEE NEXT PAGE---
<table>
<thead>
<tr>
<th>Section</th>
<th>Document</th>
<th>Requirement/Purpose</th>
<th>File Location</th>
<th>Reference (GCP and Local)</th>
<th>Exempt</th>
<th>Non-FDA Regulated Non-Exempt Human Research</th>
<th>FDA Regulated</th>
<th>IND/IDE</th>
<th>Sponsor Investigator</th>
</tr>
</thead>
<tbody>
<tr>
<td>ED-1</td>
<td>Protocol</td>
<td>To document investigator and sponsor agreement to the protocol, amendments and CRFs; and, to document revisions of trial-related documents that take effect during trial:  • Initial version that the site was registered  • Amendments and Letters of Amendment  • Subsequent versions  • Investigator signature page  * NOTE: For IRB Exempt studies. IRB Exempt Application should be on file  * NOTE: For Non-FDA Regulated Non-Human Research, Form C and/or Protocol should be present.</td>
<td>Regulatory binder</td>
<td>• 21CFR312/812  • ICH Guidance: E6 GCP, Sections 1.44, 1.45, 4.5, 5.23, 6, 8.2.2, 8.3.2</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>ED-2</td>
<td>Protocol</td>
<td>Documentation that trial procedures were reviewed with the investigator and investigator's trial staff:  • Summary of start-up calls  • Training meetings (Initiation, Implementation, Investigator Meeting, Teleconference, List of Training Attendees)</td>
<td>Regulatory binder</td>
<td>• 21CFR312/812  • ICH Guidance: E6 GCP, Sections 4.5, 5.23, 8.2.20 AAHRPP Element: III.2.A; I.1.D; UTHSCSA IRB Investigator's Handbook</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Section</td>
<td>Document</td>
<td>Requirement/Purpose</td>
<td>File Location</td>
<td>Reference (GCP and Local)</td>
<td>Exempt</td>
<td>Non-FDA Regulated Non-Exempt Human Research</td>
<td>FDA Regulated</td>
<td>IND/IDE</td>
<td>Sponsor Investigator</td>
</tr>
<tr>
<td>---------</td>
<td>----------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td>--------</td>
<td>------------------------------------------</td>
<td>---------------</td>
<td>----------</td>
<td>---------------------</td>
</tr>
</tbody>
</table>
| ED-3    | Delegation Log/Signature Log (IRB Personnel List) | 1. To document the signatures of individuals using initials in place of a full signature to sign CRFs and source documents.  
2. To document the signatures and initials of all persons authorized to make entries and/or corrections on CRFs. Include all site staff engaged in research, such as:  
• Clinicians  
• Physicians  
• Pharmacists  
• Data personnel  
• Any other individuals authorized to make entries and/or corrections on CRFs.  
3. Key/log must include:  
• Initials  
• Printed Signature  
• Legal Signature, including first and last name  
• Credentials (if appropriate)  
4. To document Principal Investigator delegation of study-related task to staff. To outline the roles and responsibilities delegated by the PI to each team member. Use IRB Personnel List for Exempt Studies. | Regulatory binder | • ICH Guidance: E6 GCP, Section 8.3.24  
AAHRPP Elements: III.2.A; III.2.B; VHA Policy Memo 151-07-07; VHA Handbook 1200.05 62c; Handbook of Operating Procedures, Section 5.8.12 | No        | Yes                                      | Yes           | Yes       | Yes                                |
<table>
<thead>
<tr>
<th>Section</th>
<th>Document</th>
<th>Requirement/Purpose</th>
<th>File Location</th>
<th>Reference (GCP and Local)</th>
<th>Exempt</th>
<th>Non-FDA Regulated</th>
<th>Non-Exempt Human Research</th>
<th>FDA Regulated</th>
<th>IND/IDE</th>
<th>Sponsor Investigator</th>
</tr>
</thead>
<tbody>
<tr>
<td>ED-4</td>
<td>Curriculum Vitae (CV) Medical License, RN License, etc. (if applicable)</td>
<td>1. The site must have on file CVs and/or other relevant documents (License, Scope of Practice, CITI or WCG Academy) evidencing qualifications and eligibility to conduct the trial and/or provide medical supervision of subjects. Includes the following key personnel: • Principal investigator (i.e., individual responsible for the grant/contract at the site). • Investigator responsible for day-to-day activities of the site. • For IND studies: Investigator of Record (IOR) All other investigators/sub-investigators and any other clinicians listed on a Form FDA 1572, Box # 6. • For non-IND studies, all other investigators/ sub-investigators and any other clinicians listed on an authorized prescribers list. • Study coordinator • Pharmacist of record 2. Update to reflect significant changes: • Affiliation • Education • Responsibilities</td>
<td>Regulatory binder</td>
<td>- 21CFR312/812 • ICH Guidance: E6 GCP, Sections 4.1, 4.3, 5.6, 8.2.10, 8.3.5 AAHRPP Element: III.2.A; I.1.D; UTHSCSA IRB Investigator’s Handbook</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Section</td>
<td>Document</td>
<td>Requirement/Purpose</td>
<td>File Location</td>
<td>Reference (GCP and Local)</td>
<td>Exempt</td>
<td>Non-FDA Regulated Non-Exempt Human Research</td>
<td>FDA Regulated</td>
<td>IND/IDE</td>
<td>Sponsor Investigator</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>----------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td>---------</td>
<td>--------------------------------------------</td>
<td>---------------</td>
<td>----------</td>
<td>---------------------</td>
<td></td>
</tr>
</tbody>
</table>
| ED-5    | ED-5     | 1. To document financial aspects of the trial and the financial agreement between the investigator / institution and the sponsor for the trial.  
2. Certification or Disclosure  
   • Certify that there is no financial interest, or  
   • Disclose specific financial interests.  
3. Applies to investigators and sub-investigators  
4. Applies to individuals who fit any of the following criteria:  
   • Sign the Form FDA 1572 (Investigator of Record)  
   • Identified as an investigator in initial submissions or protocol amendments under an IND.  
   • Identified as an investigator in the NDA (Non-Disclosure Agreement).  
   • For studies not conducted under an IND, the individuals whom the sponsor considers to be investigators and sub-investigators.  
   • Individuals who actually conduct and take responsibility for an investigation.  
   • Individuals who have the ability and opportunity to significantly impact the data as determined by the site.  
   • Spouses and dependent children of individuals indicated above.  
5. The IRB may have additional requirements.                                                                                                                                                                                                 | Regulatory binder | • 21CFR54  
• 42CFR50, Subpart F  
• 21CFR312 /812  
• ICH Guidance: E6 GCP, Section 8.2.4  
• FDA Guidance: Financial Disclosure by Clinical Investigators  
• NIH Notice OD-00-040 | No         | No                           | Yes                  | Yes                  | Yes                  | Yes                  |
<p>| ED-5a   | ED-5a    | For local research, Form X for Conflict of Interest and iDisclose forms.                                                                                                                                                                                                                   | Regulatory Binder | UTHSCSA H.O.P.: OCR Policy##                                      | Yes         | Yes                             | Yes                  | Yes                  | Yes                  |</p>
<table>
<thead>
<tr>
<th>Section</th>
<th>Document</th>
<th>Requirement/Purpose</th>
<th>File Location</th>
<th>Reference (GCP and Local)</th>
<th>Exempt</th>
<th>Non-FDA Regulated Non-Exempt Human Research</th>
<th>FDA Regulated</th>
<th>IND/IDE</th>
<th>Sponsor Investigator</th>
</tr>
</thead>
</table>
| ED-6    | IRB Approved Informed Consent Document | 1. Written informed consent form to document that consent is:  
• Obtained in accordance with regulations, GCP, and protocol.  
• Dated prior to participation of each subject in trial.  
• Provided for direct access to records.  
2. Non-English speaking subjects must be consented in a language they can understand.  
• Save all written translations.  
3. Consents obtained for screening purposes must be retained even if the subject was not enrolled in the protocol.  
4. To document revisions of these trial-related documents that take effect during trial, save all versions submitted and approved by site’s IRB:  
• Informed consent form.  
• Any other written information provided to subjects.  
5. Continuing reviews are at the directive of the IRB.  
6. Changes in consent forms due to protocol amendments and important safety information must be submitted and approved by the IRB.  
NOTE: Waiver of consent documentation has been granted by FDA and/or IRB may apply to ANY category of study. | Regulatory binder | • 45CFR46  
• 21CFR50  
• 21CFR56  
• 21CFR312  
• 812  
• ICH Guidance: E6 GCP, Sections 1.28, 4.8, 8.3.12, 8.2.3, 8.3.2  
• OHRP Informed Consent Guidance Information | No | Yes | Yes | Yes | Yes |
| ED-7    | Assent Form | • Assent of children and permission of parents or legal guardians as determined by the IRB/IEC is required as per the provisions of 45CFR46.  
• State law where the research is taking place defines the age of a minor and requirements for emancipation.  
• The Assent Form is used for children ages 7-17 (IRB may require assent in ages 7-12 and assent is usually required in ages 13-17 unless waived by the IRB).  
• The requirement for assent of children and/or permission of their parents or legal guardians may be waived by the IRB as long as the criteria for waiving consent in the regulations (45CFR46) are met.  
• Keep on file all versions submitted and approved by the IRB.  
NOTE: Waiver of consent documentation has been granted by FDA and/or IRB may apply to ANY category of study. | Regulatory binder | • 45CFR46, Subpart D  
• 21CFR50  
• 21CFR56  
• FDA Information Sheets, Guidance for IRBs and Investigators 1998 Update | No | Yes | Yes | Yes | Yes |

https://hsshare.uthscsa.edu/sites/OCR/OCR Policies/Research Files Data Management Matrix Revised 5-9-14  
Version 1.1
<table>
<thead>
<tr>
<th>Section</th>
<th>Requirement/Purpose</th>
<th>File Location</th>
<th>Reference (GCP and Local)</th>
<th>Exempt</th>
<th>Non-FDA Regulated</th>
<th>Human Research</th>
<th>FDA Regulated</th>
<th>IND/IDE</th>
<th>Sponsor Investigator</th>
</tr>
</thead>
</table>
| ED-8    | 1. Copies of all materials submitted to the IRB, including any local committees as required by the IRB, for example but not limited to:  
- CTRC's PRC  
- Radiation Use Committee  
- Other Hospital or UTHSCSA affiliate's Committees per IRB requirements  
2. Dated proof of submission and IRB approval of the following for both initial submissions and revisions (if any). Revised documents must be labeled (e.g., date and/or version number) to differentiate them from previous versions.  
- Advertisements – to document that recruitment measures are appropriate and not coercive.  
- Continuing/interim review of trial in accordance with federal regulations and IRB policy.  
- Stamped informed consent form  
- Protocol  
- Protocol Amendments and/or Letters of Amendment  
- Protocol-specific education materials  
- Subject compensation  
- Any other documents receiving IRB approval or review, including UPIRSO and Noncompliance Determinations  
- Any other written information to be provided to subjects, to document that subjects will be given appropriate written information (content and wording) to support their ability to give fully informed consent.  
- Any other pertinent communications with IRB or documentation required by the IRB.  
- Clarification memos as required by the IRB.  
3. Dated proof of IRB submission of the following for both initial submissions and revisions (if any). Revised documents must be labeled (e.g., date and/or version number) to differentiate them from previous versions.  
- Stamped informed consent form  
- Protocol  
- Protocol Amendments and/or Letters of Amendment  
- Protocol-specific education materials  
- Subject compensation  
- Any other documents receiving IRB approval or review, including UPIRSO and Noncompliance Determinations  
- Any other written information to be provided to subjects, to document that subjects will be given appropriate written information (content and wording) to support their ability to give fully informed consent.  
- Any other pertinent communications with IRB or documentation required by the IRB.  
- Clarification memos as required by the IRB. | Regulatory binder | 45CFR46  
21CFR50  
21CFR56  
21CFR312/812  
ICH Guidance: E6 GCP, Sections 3, 4.4, 4.5, 4.10, 5.11, 5.17.3, 8.2.3, 8.2.7, 8.3.2, 8.3.3, 8.3.19  
OHRP IRB Guidebook | Yes | Yes | Yes | Yes | Yes |
| ED-9    | 1. To document that subjects will be given appropriate written information (content and wording) to support their ability to give fully informed consent.  
2. To document that recruitment measures are appropriate and not coercive.  
3. Includes the following:  
- IRB-approved stamped informed consent form (long or short forms)  
- All applicable translations  
- Advertisement for subject recruitment (if used)  
- Education materials (protocol specific)  
- Any other written information, including screening and consent scripts  
- Protocol specific diaries and questionnaires | Regulatory binder | 45CFR46  
21CFR50  
21CFR56  
ICH Guidance: E6 GCP, Sections 4.8, 8.2.3 | No | Yes | Yes | Yes | Yes |
<table>
<thead>
<tr>
<th>Section</th>
<th>Document</th>
<th>Requirement/Purpose</th>
<th>File Location</th>
<th>Reference (GCP and Local)</th>
<th>Exempt</th>
<th>Non-FDA Regulated</th>
<th>Non-Exempt Human Research</th>
<th>FDA Regulated</th>
<th>IND/IDE</th>
<th>Sponsor Investigator</th>
</tr>
</thead>
</table>
| ED-10   | Screening and Enrollment / Randomization Logs | 1. To document identification of subjects who entered pretrial screening.  
2. To document chronological enrollment of subjects by trial number  
3. Screening and enrollment/randomization logs may be separate or combined.  
4. Include the following information:  
   • Initials of all patients screened for each study  
   • Study ID if patient receives one  
   • Date screened  
   • Date randomized – If not randomized, indicate reason (screen failure - labs not within protocol specific range, meets exclusion criteria, etc.)  
5. The log may also include current information regarding dates of subject visits and overall status in the study (completed, in progress, lost to follow up). | Regulatory binder | 21CFR312/812  
ICH Guidance: E6 GCP, Sections 8.3.20, 8.3.22 | Yes | Yes | Yes | Yes | Yes | Yes |
| ED-11   | Subject Identification Code List | 1. To document that the investigator keeps a confidential list of names of all subjects allocated to trial numbers upon enrolling in the trial.  
2. Allows investigator/institution to permit identification of all subjects enrolled in the trial in case followup is required.  
3. List needs to be kept in a confidential manner. | Regulatory Binder(file at the end of study) Also file in study financial binder during the study. | ICH Guidance: E6 GCP, Sections 1.58, 8.3.21, 8.4.3 | Yes | Yes | Yes | Yes | Yes | Yes |
| ED-12   | Double Blinding | To protect the integrity of the research data. A copy of the Sponsor’s SOP for unblinding must be on file at the site. | Regulatory binder | 21CFR312  
ICH Guidance: E6 GCP, Sections 1.10, 4.7, 8.2.17, 8.4.6 | No | No | Yes | Yes | Yes |
| ED-13   | Inv Product Accountability Log/Pharmacy Accountability Records | Accountability records must be kept for all study drugs/agents/devices provided as part of the protocol (including temperature logs, excursions, product shipment or receipts, dispensation logs, destruction records if done locally, expired products, product returned to sponsor). Drug/device should be stored in OCR-approved location. | Regulatory binder | 21CFR312/812  
ICH Guidance: E6 GCP, Sections 4.6, 5.13, 5.14, 8.2.15, 8.3.8, 8.3.23, 8.4.1 | No | No | Yes | Yes | Yes | Yes |
<table>
<thead>
<tr>
<th>Section</th>
<th>Document</th>
<th>Requirement/Purpose</th>
<th>File Location</th>
<th>Reference (GCP and Local)</th>
<th>Exempt</th>
<th>Non-FDA Regulated</th>
<th>Non-Exempt Human Research</th>
<th>FDA Regulated</th>
<th>IND/IDE</th>
<th>Sponsor Investigator</th>
</tr>
</thead>
</table>
| ED-14   | Record of Retained Body Fluids and/or Tissue Samples | If any blood specimens, other body fluids and/or tissue samples are retained for long-term storage at the site, document location and identification of the study related retained samples. (e.g., A laboratory data management or tracking system.) | Regulatory binder | • ICH Guidance: E6 GCP, Section 8.3.25  
• OHRP Guidance: Issues to Consider in the Research Use of Stored Data or Tissues | Yes | Yes | Yes | Yes | Yes |
| ED-15   | Serious Adverse Events (SAE) and Safety Reports | 1. Notification by originating investigator to sponsor of serious adverse events, related reports, and other safety information.  
2. Notification by sponsor to investigators of safety information.  
3. Where applicable, notification by sponsor or investigator to regulatory authorities and the IRB:  
• Unexpected, serious and related adverse drug reactions (within 5 days)  
• Other safety information (at yearly review)  
• IND Safety Reports, Safety Memos, and Safety Alerts (reported with yearly renewal, unless serious, unexpected and related to study, in which case, reported within 5 days of becoming aware of the event.)  
• Investigator’s Brochures  
• UPIRSO Determinations  
Local and non-local adverse events reviewed by PI | Regulatory binder | • 45CFR46  
• 21CFR50  
• 21CFR56  
• 21CFR312  
• ICH Guidance: E6 GCP, Sections 1.1, 1.2, 1.50, 1.60, 4.11, 5.16, 5.17, 8.3.16, 8.3.17, 8.3.18 | No | Yes | Yes | Yes | Yes |
| ED-16   | Source Document Template | To include original source document template and current version if applicable provided by sponsor related to trial. | Regulatory binder | • 21 CFR11  
• 21CFR312  
• ICH Guidance: E6 GCP, Section 1.51, 1.52, 5.20, 8.3.13 | No | Yes | Yes | Yes | Yes |
| ED-17   | Monitoring Log | Dated signature of monitor for each study visit. | Regulatory binder | • 21CFR312 /812  
• FDA Guidance: Monitoring  
• ICH Guidance: E6 GCP, Section 5.18 | No | No | Yes | Yes | Yes |
<table>
<thead>
<tr>
<th>Section</th>
<th>Document</th>
<th>Requirement/Purpose</th>
<th>File Location</th>
<th>Reference (GCP and Local)</th>
<th>Exempt</th>
<th>Non-FDA Regulated Human Research</th>
<th>FDA Regulated</th>
<th>IND/IDE</th>
<th>Sponsor Investigator</th>
</tr>
</thead>
<tbody>
<tr>
<td>ED-18</td>
<td>Monitoring Reports</td>
<td>Copies of all site visit reports (hard copy or electronic) to document both the site visits and findings of the monitor. The local PI should document how the monitor findings were addressed. *Pre-study visit, Site Initiation visit, Interim Visits and Study Close out Visit.</td>
<td>Regulatory binder</td>
<td>21CFR312/812, ICH Guidance: E6 GCP, Sections 1.39, 5.18, 8.3.10</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>ED-19</td>
<td>Final / CloseOut Monitoring Report</td>
<td>1. A close-out report by the monitor to document that all activities required for site close-out are completed and essential documents are in the appropriate files. Includes the following: • Disposition of subjects • Location of research records • Disposition of specimens • Disposition of study drug • IRB notification  2. Applies only to sites being closed (i.e., no longer enrolling new subjects or following any subjects on-study)</td>
<td>Regulatory binder</td>
<td>21CFR312/812, ICH Guidance: E6 GCP, Sections 4.13, 8.4.5</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>ED-20</td>
<td>Final Study Report</td>
<td>Final report by the investigator to the IRB, and where applicable, to the regulatory authorities to document completion of the trial. Include the following information: • Disposition of subjects • Location of research records • Disposition of specimens • Disposition of study drug • Other information as required by the IRB (e.g., number of patients screened, number enrolled, serious adverse experiences, etc.).</td>
<td>Regulatory binder</td>
<td>21CFR312/812, ICH Guidance: E6 GCP, Sections 4.13, 8.4.7</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>
### UTHSCSA
Institutional Research Documentation Standards

<table>
<thead>
<tr>
<th>Section</th>
<th>Document</th>
<th>Requirement/Purpose</th>
<th>File Location</th>
<th>Reference (GCP and Local)</th>
<th>Exempt</th>
<th>Non-FDA Regulated</th>
<th>Non-Exempt Human Research</th>
<th>FDA Regulated</th>
<th>IND/IDE</th>
<th>Sponsor Investigator</th>
</tr>
</thead>
</table>
| ED-21   | Communications/Correspondence | 1. All important significant communications, other than site visits, to document any agreements or significant discussions regarding trial administration, protocol violations, trial conduct, adverse event (AE) reporting, etc. For example:  
- Letters  
- Meeting notes  
- Notes of telephone calls  
- Email messages  
- Faxes  
2. Includes significant communications to and from the Sponsor.  
3. Communications about a specific subject must be filed with source documents in the subject’s research record.  
4. Save electronic media, originals, and/or certified copies. | Regulatory binder |  
- ICH Guidance: E6 GCP, Sections 4.4, 4.9, 8.3.11 | No | No | Yes | Yes | Yes |
| ED-22   | Form FDA 1572 (Statement of Investigator) | 1. Required for each initial protocol registration submission of a new protocol with an Investigational New Drug (IND) application (Form FDA 1571)  
2. The Investigator listed in Box 1 of the 1572 is the individual who must sign and date the form. This individual is referred to as the Investigator of Record (IOR).  
3. Only laboratories not specified in the protocol need to be listed in Section 4.  
4. Section 6 must list any individual:  
- Responsible for the medical management of subjects.  
- Authorized to prescribe study medication.  
- This may include, but is not limited to, the following:  
  - MDs  
  - Pharmacists  
  - Nurse Practitioner  
  - Physician’s Assistant  
  - Study Coordinator  
- If there are no individuals that need to be listed, then record “NONE”.  
5. Update as study personnel and/or other data on the form change. Updated forms must be signed and dated by the IOR.  
6. The original version and any updated forms must be submitted to the sponsor (if applicable) and the FDA.  
7. A copy of the forms must be kept on file at the site. | Regulatory binder |  
- 21CFR312  
- ICH Guidance: E6 GCP, Sections 4.1, 4.3 | No | No | No | Yes | Yes |
<table>
<thead>
<tr>
<th>Section</th>
<th>Document</th>
<th>Requirement/Purpose</th>
<th>File Location</th>
<th>Reference (GCP and Local)</th>
<th>Exempt</th>
<th>Non-FDA Regulated Non-Exempt Human Research</th>
<th>FDA Regulated</th>
<th>IND/IDE</th>
<th>Sponsor Investigator</th>
</tr>
</thead>
<tbody>
<tr>
<td>ED-23</td>
<td>Investigator's Brochure (IB) /Device Brochure/ Package Insert or Equivalent</td>
<td>1. To document that relevant and current scientific information about the investigational drug/agent has been provided to the investigator. 2. Include updates to document that investigator is informed in a timely manner of relevant information as it becomes available. 3. Keep on file a copy for EACH of the study drugs/agents used within the protocol. 4. Include the following: • Original versions • Addendum to IBs (e.g., all INDsafety reports related to the drug/agent).</td>
<td>Regulatory binder</td>
<td>• 21CFR312 • ICH Guidance: E6 GCP, Sections 1.36, 5.12, 7, 8.2.1, 8.3.1</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>ED-24</td>
<td>Laboratory</td>
<td>1. To document competence of local, central, or Group laboratories to perform protocol required tests and support reliability of results of medical/laboratory/standardized procedures/tests, one of the following must be on file: • CLIA Certification of Compliance • CLIA Certification of Accreditation AND the agency certificate (e.g., CAP Certification of Accreditation)</td>
<td>Regulatory binder</td>
<td>• 21CFR58 • 21CFR312 • 42CFR493.3 • ICH Guidance: E6 GCP, Sections 4.2, 8.2.11, 8.2.12 8.3.6, 8.3.7</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>ED-24</td>
<td>SOP/Manual of Operations</td>
<td>Protocol Specific</td>
<td>Regulatory Binder</td>
<td></td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

[Source: hscshare.uthscsa.edu/sites/OCR/OCR Policies/Research Files Data Management Matrix Revised 5-9-14 Version 1.1]
<table>
<thead>
<tr>
<th>Section</th>
<th>Document</th>
<th>Requirement/Purpose</th>
<th>File Location</th>
<th>Reference (GCP and Local)</th>
<th>Exempt</th>
<th>Non-FDA Regulated Non-Exempt Human Research</th>
<th>FDA Regulated</th>
<th>IND/IDE</th>
<th>Sponsor Investigator</th>
</tr>
</thead>
</table>
| SD-1    | Hospital, clinic, office records, Progress notes, medical history, Subject diaries, study questionnaires, Laboratory report/x-ray reports/ECG report | 1. To document the existence of the subject and substantiate integrity of trial data collected. 2. To include original documents related to the trial, medical treatment, history of subject, and subject’s condition while on-study or in follow-up. 3. PI should ensure out-of-range labs are reviewed with subject and assessed. *NOTE: For Exempt studies, Questionnaires would be in this section. Electronic media, original documents or certified copies | Source Document Binder | • 21CFR11  
• 21CFR312/812  
• FDA Guidance: E6 GCP, Sections 1.51, 1.52, 5.20, 8.3.13 | Yes | Yes | Yes | Yes | Yes |
<p>| SD-2    | Inclusion/Exclusion Checklist, Study visit Evaluation checklist | To document subject eligibility in the study. First recording of study specific NOTE: regulatory exclusions (prisoners, employees, students, etc.) | Source document Binder | | No | Yes | Yes | Yes | Yes |</p>
<table>
<thead>
<tr>
<th>Section</th>
<th>Document</th>
<th>Requirement/Purpose</th>
<th>File Location</th>
<th>Reference (GCP and Local)</th>
<th>Exempt</th>
<th>Non-FDA Regulated</th>
<th>Non-Exempt Human Research</th>
<th>FDA Regulated</th>
<th>IND/IDE</th>
<th>Sponsor Investigator</th>
</tr>
</thead>
<tbody>
<tr>
<td>SD-3</td>
<td>Signed informed consent including Assent, HIPPA, Subject Bill of Rights</td>
<td>1. Written informed consent form to document that consent is: • Obtained in accordance with regulations, GCP, and protocol. • Dated prior to participation of each subject in trial. Provided for direct access to records. • Completed (signature/date/time/check box/initials) and signed by corresponding persons. 2. Consent process is documented and subject is given a copy of the signed document.</td>
<td>Source Document Binder</td>
<td>OHRP Informed Consent Guidance Information</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>SD-4</td>
<td>Note to File (Memos), Correspondence (subject related)</td>
<td>Study related NTF on subject participant Documentation of phone contact, email or mail</td>
<td>Source Document Binder</td>
<td></td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>SD-5</td>
<td>Concomitant medication list, adverse event, SAE, Procedure form</td>
<td>Document subject's concomitant medication before and during the trial, any adverse event, surgical/treatment procedures or serious adverse event. Documentation adverse events were reviewed by the PI.</td>
<td>Source Document Binder</td>
<td></td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Section</td>
<td>Document</td>
<td>Requirement/Purpose</td>
<td>File Location</td>
<td>Reference (GCP and Local)</td>
<td>Exempt</td>
<td>Non-FDA Regulated</td>
<td>FDA Regulated</td>
<td>IND/IDE</td>
<td>Sponsor Investigator</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>----------</td>
<td>---------------------</td>
<td>---------------</td>
<td>---------------------------</td>
<td>--------</td>
<td>-------------------</td>
<td>--------------</td>
<td>---------</td>
<td>---------------------</td>
<td></td>
</tr>
</tbody>
</table>
| DC-1    | Case Report Forms/Data Collection Forms (both electronic and paper) | 1. Dated, completed case report forms (CRFs):  
• To document that the investigator or authorized member of the investigator’s staff confirms the observations recorded.  
• To document all changes/additions or corrections made to CRFs after initial data were recorded.  
• Signed if required by Group SOPs or if used as source documentation.  
2. Originals retained by sponsor after study completion and/or site closure.  
3. Site retains copy. If eCRFs are being used, ensure eCRFs meet all electronic security precautions for protection of PHI. | File (CD for eCRF) in regulatory binder | • 21CFR312/812  
• FDA Guidance: E6 Good Clinical Practice (GCP), Sections 1.11, 4.9, 5.5, 5.23, 8.3.14, 8.3.15 | No | No | Yes | Yes | Yes |
## FN-1 Coverage Analysis
Coverage Analysis is a document that outlines what clinical procedures may be paid by Medicare/Insurance, and what procedures must be paid by the study. Consists of two parts: Qualifying Clinical Trial form and Billing Grid (RABT if applicable).

- **File Location**: Study Specific Financial File
- **Reference (GCP and Local)**: HOP 7.7.1, OCR Policy#1.3.2
- **Study Involves Clinical Services (Step 1 and 2)**: Yes
- **Participant Payment (Step 1)**: No

## FN-2 Internal Budget
Internal Budgets for all Clinical Trials are based on the coverage analysis and on the contract (if applicable).

- **File Location**: Study Specific Financial File
- **Reference (GCP and Local)**: OCR Policy #1.1.1, OCR Policy #1.3.2
- **Study Involves Clinical Services (Step 1 and 2)**: Yes
- **Participant Payment (Step 1)**: Yes

## FN-3 Feasibility Assessment
Outlines the scientific importance for the study and balances it with probability of accrual and financial solvency.

- **File Location**: Study Specific Financial File
- **Reference (GCP and Local)**: OCR Policy#1.1.1
- **Study Involves Clinical Services (Step 1 and 2)**: Yes
- **Participant Payment (Step 1)**: Yes

## FN-4 Billing Statements
Monthly billing statements are provided to every coordinator.

- **File Location**: Study Specific Financial File
- **Study Involves Clinical Services (Step 1 and 2)**: Yes
- **Participant Payment (Step 1)**: Yes

## FN-5 RABT
The Research Activity Billing Trigger (RABT) enables tracking of each patient's study events while on study.

- **File Location**: Study Specific Financial File
- **Reference (GCP and Local)**: HOP 7.7.1, OCR Policy#1.3.2
- **Study Involves Clinical Services (Step 1 and 2)**: Yes
- **Participant Payment (Step 1)**: Yes

## FN-6 Signed Agreements
To document agreements between the involved parties, if any. These must be signed by an individual authorized by the Institution to sign on behalf of The Regents of the University of Texas. This includes:

- **CDA** - Confidential Disclosure Agreements
- **NDA** - Non-Disclosure Agreements
- **MTA** - Material Transfer Agreements
- **CTA** - Clinical Trial Agreements

For Example:
- Investigator/Institution and Sponsor (e.g., contracts, grants)
- Investigator/Institution and Affiliated Sites (e.g., contracts)
- Investigator/Institution and Authorities (where required)

- **File Location**: Study Specific Financial File
- **Reference (GCP and Local)**: HOP 7.7.1, OCR Policy#1.3.2
- **Study Involves Clinical Services (Step 1 and 2)**: Yes
- **Participant Payment (Step 1)**: Yes

## FN-7 Subject Identification Code List

1. To document that the Investigator keeps a confidential list of names of all Subjects allocated to Trial numbers upon enrolling in the Trial.
2. Allows Investigator/Institution to permit Identification of all Subjects enrolled in the Trial in case follow-up is required.
3. List needs to be kept in a confidential manner. NOTE: **DO NOT KEEP FINANCIAL INFORMATION within the research subject record.** The Subject ID log (enrollment key) must be readily available to reconcile payments to subjects.

- **File Location**: Study Specific Financial File
- **Reference (GCP and Local)**: OCR Policy#1.3.2, GCP E6, Sections: 1.58, 8.3.21, 8.4.3
- **Study Involves Clinical Services (Step 1 and 2)**: Yes
- **Participant Payment (Step 1)**: Yes

## FN-8 Participant Reimbursement
1. To document the payments issued to research participants equal the consent form language.
2. To ensure adequate internal business control of payment inventory
3. To maintain auditable financial records.

- **File Location**: Study Specific Financial File
- **Reference (GCP and Local)**: HOP 7.7.2, OCR Participant Payment Guide
- **Study Involves Clinical Services (Step 1 and 2)**: Yes
- **Participant Payment (Step 1)**: Yes